Despite the enormous public health problem caused by obesity and its metabolic complications, available treatments are limited.

In the early 2000s, cannabinoid type 1 receptor (CB~1~R) inverse agonists represented a very interesting class of molecules, since Rimonabant, the first in class brain-penetrant CB~1~R inverse agonist, was shown not only to reduce body weight but also to improve all of obesity metabolic sequelae (reviewed in [@bib1]). In 2006, Rimonabant (Acomplia) went on the European market for the treatment of obesity. However, a couple of years later the drug was withdrawn from the market due to its psychiatric side effects. This event dramatically affected the pharmaceutical industry and the academic world alike and the interest in the endocannabinoid system (ECS) and the CB~1~R as potential therapeutic targets for metabolic disease dramatically dropped. That is until 2010, when a study described the ability of a peripherally-restricted CB~1~R antagonist to effectively reduce obesity and cardiometabolic risk in diet-induced obese (DIO) mice [@bib2]. This initial study, together with others published over the past 7 years, has strongly helped expand our knowledge on the role of the ECS in the regulation of energy balance and metabolism, positioning the CB~1~R at the cornerstone of these physiological mechanisms and once again at center stage as a therapeutic target for obesity and metabolic disorders [@bib1].

In this issue of *Molecular Metabolism*, Joseph Tam and colleagues now investigate the hypothalamic targets of JD5037-induced leptin sensitization in DIO mice [@bib3]. JD5037 is a peripherally-restricted CB~1~R inverse agonist that the same authors first described in a study published in 2012 [@bib4]. In this earlier paper, the authors demonstrated that the ability of JD5037 to reduce food intake, body weight, and fat mass was due to the rapid (within 48 h) reduction of circulating hyperleptinemia and consequent re-establishment of the molecular response to endogenous leptin in the hypothalamus of DIO mice [@bib4]. The current work further expands onto this notion, providing evidence that the JD5037 leptin-dependent effects on food intake and adiposity occur via activation of hypothalamic arcuate nucleus pro-opio-melanocortin (POMC) neurons, which are known to also participate to cannabinoids-induced feeding [@bib5], and the related melanocortin MC4R signaling [@bib3]. Indeed, the hypophagia and weight loss effects of JD5037 were substantially blunted in mice genetically lacking MC4R (MC4R-KO) or in DIO mice receiving the MC4R antagonist SHU-9119 [@bib3]. Differently, treatment with Rimonabant significantly reduced food intake and body weight in MC4R-KO mice [@bib3], implying that Rimonabant exerts its actions on food intake and body weight through mechanisms other than the hypothalamic melanocortin pathway [@bib6], [@bib7]. The authors also now demonstrate that treatment of DIO mice with JD5037 significantly reduced hypothalamic levels of anandamide, a major endocannabinoid, entailing a possible reduction in hypothalamic CB~1~R signaling [@bib3], which, in turn, might have facilitated MC4R signaling [@bib8]. Although not investigated by the authors, it is also expected that leptin-induced activation of POMC neurons was concomitantly accompanied by inhibition of agouti-related protein (AgRP) neurons and decreased release of the endogenous MC4R inverse agonist AgRP, as leptin is known to oppositely act on hypothalamic POMC and AgRP neurons. Leptin-dependent inhibition of AgRP neurons (and consequent disinhibition of melanocortin MC4R signaling) might actually be important in order to explain the effects of JD5037 on food intake and body weight, considering that this compound was effective in inducing hypophagia and weight loss in *Magel2*-KO mice [@bib9], a model of Prader--Willi syndrome in which leptin is unable to depolarize POMC neurons [@bib10]. This evidence would indeed suggest that leptin-induced activation of POMC neurons [@bib3] is not necessary in order to observe the JD5037 leptin-dependent decrease in appetite and weight. Thus, further studies are needed in order to clarify this point.

Another question that currently remains unanswered is how restored leptin sensitivity by peripheral CB~1~R inverse agonism actually results in increased hypothalamic MC4R signaling. A possibility is that the transport of leptin through the blood--brain barrier, which is defective in DIO mice, is rapidly and drastically improved by JD5037 treatment. This is a likely scenario considering that in their work published in 2012, Tam and colleagues showed that megalin, a protein involved in the transport of leptin through the blood--brain barrier, was reduced in DIO mice and restored after chronic administration of JD5037 [@bib4]. Alternatively, or in addition, circulating leptin might act through vagal afferent neurons. This is a possibility now mentioned by the authors in their discussion section [@bib3]. And indeed, it would be extremely interesting to investigate the role of both vagal and peripheral sympathetic neurotransmission in JD5037-induced hypophagia. Especially because changes in circulating leptin levels are observed only 48 h after the start of the treatment [@bib4] and do not explain the hypophagia induced by JD5037 already during the first 24 h of treatment. Thus, it is likely that the rapid, hypophagic effect of JD5037 is mediated through the inhibition of CB~1~R-dependent effects on the autonomic nervous system, as already observed for the acute, hypophagic action of rimonabant [@bib6], [@bib7], [@bib11].

Notwithstanding these open questions, the most recent data by Tam and coworkers [@bib3] demonstrate how a therapeutic molecule exclusively inhibiting peripheral CB~1~R might use "second messengers" like leptin to act onto specific brain circuits, highlighting once again the relevance of the ECS in the periphery-to brain-to periphery communication for the regulation of energy balance and metabolism.
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